Equity Method Investment in Equity Investee	9 Months Ended
Mar. 31, 2026
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment in Equity Investee	Equity Method Investment in Equity Investee The Company has accounted for its investment in the JV Company (as defined herein) using the equity method of accounting. For details of its equity method investment, please refer to Part II, Item 8, Note 2 — Equity Method Investment in Equity Investee in its 2025 Form 10-K. On July 14, 2025, the Company entered into an equity transfer agreement to sell approximately 20.3% of outstanding equity interest in the JV Company for an aggregate cash consideration of $150 million. On August 29, 2025, the amended shareholders’ agreement for the JV Company was signed, which reduced the Company’s equity interest in the JV Company by 20.3% to an ownership percentage of 18.9%. As a result, the Company received its first installment of RMB 676 million (or $94.5 million based on the currency exchange rate between RMB and U.S. Dollar on August 29, 2025), and paid transaction costs related to this sale of approximately $2.4 million. In addition, the Company received $11.1 million for the second installment payment during the three months ended December 31, 2025, and $30.3 million for the third installment payment during the three months ended March 31, 2026, and had a receivable balance of $15.6 million as of March 31, 2026, which is included in the receivable from sale of equity interest in the JV Company line on the Condensed Consolidated Balance Sheets. The remaining installment will be received subject to satisfaction of certain conditions, which require the Company's continuing involvement, including voting in shareholder meetings to complete the transaction in accordance with the equity transfer agreement, plus other administrative actions. As a result of the sales transaction, the Company evaluated the factors that indicate the ability to exercise its significant influence to the JV Company, including but not limited to representation on the board, material intra-entity transactions, and participation in policy making process. The Company concluded that it continues to have the ability to exercise significant influence over the operating and financial policies of the JV Company and accordingly accounts for the investment using the equity method of accounting. The Company reports its equity in earnings or loss of the JV Company on a three-month lag due to an inability to timely obtain financial information from the JV Company. During the three months ended March 31, 2026, the Company recorded a $0.2 million loss, using lag reporting. During the nine months ended March 31, 2026, the Company recorded $1.1 million income, including the $1.1 million gain on the related sale of a portion of its interest in the equity method investment and immaterial income of its equity share of the JV Company, using lag reporting. During the three and nine months ended March 31, 2025, the Company recorded a $0.3 million loss and a $1.8 million loss, respectively, on its equity share of the JV Company, using lag reporting, as well as a gain of $0.5 million on the change of equity interest in the JV Company.

On July 14, 2025, the Company entered into an equity transfer agreement to sell approximately 20.3% of outstanding equity interest in the JV Company for an aggregate cash consideration of $150 million. On August 29, 2025, the amended shareholders’ agreement for the JV Company was signed, which reduced the Company’s equity interest in the JV Company by 20.3% to an ownership percentage of 18.9%. As a result, the Company received its first installment of RMB 676 million (or $94.5 million based on the currency exchange rate between RMB and U.S. Dollar on August 29, 2025), and paid transaction costs related to this sale of approximately $2.4 million. In addition, the Company received $11.1 million for the second installment payment during the three months ended December 31, 2025, and $30.3 million for the third installment payment during the three months ended March 31, 2026, and had a receivable balance of $15.6 million as of March 31, 2026, which is included in the receivable from sale of equity interest in the JV Company line on the Condensed Consolidated Balance Sheets. The remaining installment will be received subject to satisfaction of certain conditions, which require the Company's continuing involvement, including voting in shareholder meetings to complete the transaction in accordance with the equity transfer agreement, plus other administrative actions. As a result of the sales transaction, the Company evaluated the factors that indicate the ability to exercise its significant influence to the JV Company, including but not limited to representation on the board, material intra-entity transactions, and participation in policy making process. The Company concluded that it continues to have the ability to exercise significant influence over the operating and financial policies of the JV Company and accordingly accounts for the investment using the equity method of accounting.

The Company reports its equity in earnings or loss of the JV Company on a three-month lag due to an inability to timely obtain financial information from the JV Company. During the three months ended March 31, 2026, the Company recorded a $0.2 million loss, using lag reporting. During the nine months ended March 31, 2026, the Company recorded $1.1 million income, including the $1.1 million gain on the related sale of a portion of its interest in the equity method investment and immaterial income of its equity share of the JV Company, using lag reporting. During the three and nine months ended March 31, 2025, the Company recorded a $0.3 million loss and a $1.8 million loss, respectively, on its equity share of the JV Company, using lag reporting, as well as a gain of $0.5 million on the change of equity interest in the JV Company.